Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00112658 |
Recruitment Status :
Completed
First Posted : June 3, 2005
Last Update Posted : March 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective as first-line therapy in treating pancreatic cancer.
PURPOSE: This randomized phase II/III trial is studying how well combination chemotherapy works as first-line therapy in treating patients with metastatic pancreatic cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Cancer | Drug: fluorouracil Drug: gemcitabine hydrochloride Drug: irinotecan hydrochloride Drug: leucovorin calcium Drug: oxaliplatin | Phase 2 Phase 3 |
OBJECTIVES:
Primary
- Compare the objective response rate in patients with metastatic adenocarcinoma of the pancreas treated with oxaliplatin, irinotecan, leucovorin calcium, and fluorouracil vs gemcitabine as first-line chemotherapy. (Phase II)
- Compare the survival of patients treated with these regimens. (Phase III)
Secondary
- Compare the toxicity of these regimens in these patients.
- Compare progression-free survival of patients treated with these regimens. (Phase III)
- Compare the overall response rate in patients treated with these regimens. (Phase III)
- Compare quality of life of patients treated with these regimens. (Phase III)
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oxaliplatin IV over 2 hours, irinotecan IV over 1½ hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days.
- Arm II: Patients receive gemcitabine IV on days 1, 8, 15, 22, 29, 36, and 43. Beginning on day 57, patients receive gemcitabine IV once weekly for 3 weeks (days 57, 64, and 71). Courses repeat every 28 days.
PROJECTED ACCRUAL: A total of 348 patients (88 for phase II and 260 for phase III) will be accrued for this study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 342 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Primary Purpose: | Treatment |
Official Title: | Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients |
Actual Study Start Date : | November 2004 |
Actual Primary Completion Date : | June 2010 |
Actual Study Completion Date : | June 30, 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: Folfirinox |
Drug: fluorouracil Drug: irinotecan hydrochloride Drug: leucovorin calcium Drug: oxaliplatin |
Active Comparator: Gemcitabine |
Drug: gemcitabine hydrochloride |
- Objective response rate (Phase II)
- Survival (Phase III)
- Toxicity
- Progression-free survival (Phase III)
- Quality of life (Phase III)
- Overall response rate (Phase III)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically or cytologically confirmed adenocarcinoma of the pancreas
-
No other pancreatic tumor type, including either of the following:
- Neuroendocrine tumor
- Acinar cell tumor
- Metastatic disease
-
- Measurable disease in an area not previously irradiated
- No cerebral metastases or meningeal involvement of the tumor
PATIENT CHARACTERISTICS:
Age
- 18 to 75
Performance status
- WHO 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (biliary drainage allowed)
Renal
- Creatinine < 120 mmol/L
Cardiovascular
- No prior myocardial infarction
- No prior angina
- No uncompensated cardiac or coronary insufficiency
- No symptomatic arrhythmia
Gastrointestinal
- No prior inflammatory bowel disease
- No prior chronic diarrhea
- No unresolved symptomatic occlusion or subocclusion of the bowel
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No ongoing active infection
- No other malignancy except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No contraindication to study treatment
- No other serious medical disorder that would preclude study treatment
- No psychiatric disorder or social or geographic situation that would preclude study participation
- Not detained or under the guardianship of another person
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy
Surgery
- Not specified
Other
- No concurrent participation in another clinical trial using therapeutic experimental agents
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00112658
Study Chair: | Thierry Conroy, MD | Centre Alexis Vautrin |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | UNICANCER |
ClinicalTrials.gov Identifier: | NCT00112658 |
Other Study ID Numbers: |
CDR0000430100 FRE-FNCLCC-ACCORD-11/0402 EU-20512 |
First Posted: | June 3, 2005 Key Record Dates |
Last Update Posted: | March 8, 2021 |
Last Verified: | March 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
adenocarcinoma of the pancreas stage IV pancreatic cancer |
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Leucovorin Gemcitabine Fluorouracil Oxaliplatin Irinotecan Calcium Levoleucovorin |
Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Antidotes Protective Agents Vitamin B Complex Vitamins |